Tirzepatide online cost: what you'll pay in 2026

Is compounded tirzepatide still legal in 2026?

The FDA ended enforcement discretion for 503B outsourcing facilities compounding tirzepatide on March 19, 2025, once it determined the drug shortage that justified mass compounding had resolved. On April 30, 2026, the agency proposed going further, excluding tirzepatide, semaglutide, and liraglutide from the 503B bulks list entirely, finding no continuing clinical need for outsourcing facilities to compound them from bulk drug substance now that brand-name supply is stable. The public comment period on that proposal closed June 30, 2026, with no final rule announced yet. A 503A pharmacy can still legally compound tirzepatide for an individual patient when a prescriber documents a specific clinical reason, such as an allergy to an inactive ingredient in Zepbound, but compounding it purely as a lower-cost alternative to the brand is no longer the legal basis it was during the shortage years.

What affects your monthly tirzepatide cost?

Dose level

Tirzepatide is titrated up over months, from 2.5mg to as high as 15mg. LillyDirect charges more at 7.5mg and above than at the two starting doses. Ask any provider how the price changes as your dose increases.

The 45-day refill window

At 7.5mg through 15mg, LillyDirect only holds the $449 price if you refill within 45 days of your previous order. Missing that window at those doses pushes the price to $499–$699 until you catch back up.

Compounded vs brand self-pay

Compounded tirzepatide can still run cheaper than LillyDirect, but it now requires a documented patient-specific need rather than being a general substitute. For most people, Lilly's own self-pay program is the realistic option in 2026.

State regulations

Compounding rules vary by state, and not every provider ships to every state. Confirm availability in your state before applying with any program.

Medicare and the 2026 obesity-drug deal

Medicare has paid for Zepbound when it treats moderate-to-severe obstructive sleep apnea with obesity since the FDA added that indication in December 2024, but it generally still excludes weight-loss-only use. A November 2025 agreement between Eli Lilly and the U.S. government sets Medicare beneficiaries' copay at no more than $50 a month for the Zepbound multi-dose pen starting as early as April 1, 2026, with Medicare paying the remaining $245. Eligibility rules apply; see our full Medicare GLP-1 coverage breakdown.

Is tirzepatide worth the extra cost over semaglutide?

The SURMOUNT-5 head-to-head trial, published in 2025, put tirzepatide and semaglutide against each other directly in adults with obesity. At 72 weeks, tirzepatide produced an average 20.2% reduction in body weight versus 13.7% for semaglutide, along with larger improvements in blood pressure, HbA1c, fasting insulin, triglycerides, and HDL cholesterol. That gap is the clinical case for tirzepatide's higher price. Whether it is worth it for you depends on how much weight you need to lose, your tolerance for GI side effects, which tend to run slightly higher with tirzepatide, and whether a program even carries tirzepatide in your state, since availability is less consistent than for semaglutide.

Which online programs currently offer tirzepatide?

Not every program offers tirzepatide. Availability shifts with supply and FDA guidance, and some programs focus on semaglutide only, so confirm tirzepatide is in stock before you sign up.